(Q33402203)

26 July 2017

title

Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma (English)

1 reference

diffuse large B-cell lymphoma

26 July 2017

1 reference

1 reference

1 reference

2

Nancy Bartlett

1 reference

26 July 2017

6

Donald W Northfelt

1 reference

26 July 2017

Andres Forero-Torres

1

1 reference

26 July 2017

Anne Beaven

3

1 reference

26 July 2017

Han Myint

4

1 reference

26 July 2017

Sunita Nasta

5

1 reference

26 July 2017

Nancy C Whiting

7

1 reference

26 July 2017

Jonathan G Drachman

8

1 reference

26 July 2017

Albert F Lobuglio

9

1 reference

26 July 2017

Craig H Moskowitz

10

1 reference

26 July 2017

publication date

8 September 2012

1 reference

26 July 2017

1 reference

26 July 2017

volume

54

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

277-283

1 reference

26 July 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

Functions of CD40 on B cells, dendritic cells and other cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

Prospects for CD40-directed experimental therapy of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

Gemcitabine: a pharmacologic and clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

Fatal pulmonary toxicity resulting from treatment with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.710328

10.3109/10428194.2012.710328

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference